Processa Pharmaceuticals (PCSA) Projected to Post Earnings on Friday

Processa Pharmaceuticals (NASDAQ:PCSA) is anticipated to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter.

Processa Pharmaceuticals (NASDAQ:PCSA) last announced its earnings results on Thursday, March 20th. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.18. On average, analysts expect Processa Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Processa Pharmaceuticals Price Performance

PCSA stock opened at $0.39 on Friday. The firm has a 50 day simple moving average of $0.56 and a two-hundred day simple moving average of $0.93. The stock has a market cap of $1.27 million, a PE ratio of -0.12 and a beta of 0.75. Processa Pharmaceuticals has a one year low of $0.36 and a one year high of $3.31.

Insider Transactions at Processa Pharmaceuticals

In other Processa Pharmaceuticals news, CEO George K. Ng purchased 87,200 shares of the stock in a transaction on Monday, January 27th. The stock was acquired at an average cost of $0.80 per share, with a total value of $69,760.00. Following the completion of the purchase, the chief executive officer now directly owns 87,200 shares of the company’s stock, valued at approximately $69,760. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Young acquired 124,500 shares of Processa Pharmaceuticals stock in a transaction dated Monday, January 27th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $99,600.00. Following the completion of the purchase, the insider now directly owns 205,405 shares of the company’s stock, valued at approximately $164,324. The trade was a 153.88 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 224,100 shares of company stock worth $179,280. 13.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Processa Pharmaceuticals in a research report on Thursday, December 5th.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.